gemcitabine/tipifarnib

Known as: Gemcitabine/R115777, dFdC/R115777 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2009
0120002009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
In this randomized, double-blind, placebo-controlled study comparing gemcitabine+tipifarnib (G+t) or gemcitabine+placebo (G+p) in… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2007
2007
Interferon alpha (IFNalpha) induces an EGF-Ras-->Raf-1-->Erk dependent survival pathway counteracting apoptosis induced by the… (More)
Is this relevant?
2005
2005
The high incidence of activating RAS mutations, coupled with accumulating evidence linking RAS to multiple myeloma (MM… (More)
Is this relevant?
2004
2004
Ras activation is frequently observed in multiple myeloma either by mutation or through interleukin-6 receptor signaling… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2003
2003
PURPOSE Inhibitors of farnesyltransferase (e.g., R115777) are being developed for therapy and prevention of various cancers. The… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2000
2000
R115777 {(B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone} is a… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?